Serodus management

Dr. Eva Steiness

Chief Executive Officer, Serodus ApS


Eva Steiness, MD, D.Sci. professor clinical pharmacology

Postgraduate 10 years at University Hospital in Aarhus, Jutland and Rigshospitalet in Copenhagen

Dean at Medical Faculty, Copenhagen University 1981-85. Professor clinical Pharmacology Aarhus University 1985-1989

Executive Vice President, Drug Discovery & Development Lundbeck Pharma A/S 1989-1999. Was a member of the Executive Board and instrumental in the pipeline development for the IPO in 1999. Today, Lundbeck Pharma A/S is a OMX C25 index member on the Copenhagen Stock Exchange

Founder and CEO of Zealand Pharma A/S 1999-2008. The company went public in 2010 and is today a C-25 index member on the Copenhagen Stock Exchange

CEO and co-founder of Phlogo ApS 2008-2013. Acquired by Serodus AS 2013

CEO of Serodus AS from 2013 to 2023 and present the CEO of Serodus ApS which manage and develops a pipeline focused on Diabetic Nephropathy

Henrik Mordhorst

Chief Financial Officer

Mr Mordhorst holds an MSc in Economics from Copenhagen Business School, Denmark. Certified financial advisor UK/CH

30 years+ experience in finance, asset management and commercial real estate

Founder and CEO of HeMo ApS

Mr. Mordhorst joined Serodus in 2019 as consultant.

Daniel Capion

Business Development and Documentation

MSc Pharm (UCPH), Executive MBA (CBS), Diploma in Managing Medicinal Product Innovation (SIMI)

+25 years of life science experience primarily within Regulatory Operations, R&D Data & Digital Strategies
(Genmab, Ferring, LEO Pharma)

Founder and Managing Director of Documizer ApS – specializing in documentation of R&D science assets.

Mr. Capion joined Serodus in 2022 as consultant.